Search clinical trials for: Placebo to match Secukinumab, s.c.

Total 1806 results

Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects

Atopic Dermatitis

China
Merck Sharp & Dohme LLC

Completed

A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)

Parkinson's Disease
AstraZeneca

Completed

A Study of AZD4901 in Females With Polycystic Ovary Syndrome

Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder

United States, United Kingdom, Germany
AstraZeneca

Terminated

A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males

Healthy Subjects

United States
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

Ankylosing Spondylitis

India, Turkey, Belgium, Thailand, United States, Czechia, Greece, Russian Federation, Bulgaria, Guatemala, Italy, Korea, Republic of, Malaysia, Sweden, Colombia, Philippines, Poland, Brazil
Novartis Pharmaceuticals

Terminated

A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) (ORBIT)

Thyroid Eye Disease | Graves Orbitopathy

Germany
Chinese University of Hong Kong

Completed

PsA Secukinumab XCT Structural Progression Study

Psoriatic Arthritis

Hong Kong
Novartis Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma

Asthma

Germany, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) (SUNRISE)

Hidradenitis Suppurativa

Belgium, Italy, United Kingdom, United States, Hungary, Malaysia, Germany, Netherlands, France, Israel, Lebanon, Singapore, Spain, Bulgaria, Lithuania, Argentina, Turkey, Guatemala, Switzerland, Vietnam, Philippines, Croatia, India, S... and more
Novartis Pharmaceuticals

Withdrawn

Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA). (CAIN457X12301)

Active Peripheral Spondyloarthritis (pSpA)
Icahn School of Medicine at Mount Sinai
Novartis

Terminated

A Study of Secukinumab for the Treatment of Alopecia Areata

Alopecia Areata

United States
Novartis Pharmaceuticals

Terminated

Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
ObsEva SA

Completed

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PRIMROSE 1)

Uterine Fibroids | Heavy Menstrual Bleeding

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.

Psoriatic Arthritis

China
Gilead Sciences

Completed

Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION) (FUSION)

Chronic Hepatitis C

United States, Canada, New Zealand, Puerto Rico
Novartis Pharmaceuticals

Completed

Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients (ObePso-S)

Plaque Psoriasis

United States
Novartis Pharmaceuticals

Completed

This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). (SUNSHINE)

Hidradenitis Suppurativa

United States, Spain, Russian Federation, Taiwan, Germany, France, United Kingdom, Korea, Republic of, Japan, Australia, Switzerland, Austria, Italy, Sweden, India, Israel, Mexico, Philippines, Portugal, Turkey, Greece, Hungary, Bul... and more
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis (PREVENT)

Non-radiographic Spondyloarthritis

United States, Spain, Belgium, Hungary, Turkey, Netherlands, Austria, Israel, Sweden, Switzerland, Germany, Korea, Republic of, Australia, Russian Federation, Italy, Portugal, United Kingdom, Bulgaria, France, Czechia, Poland, Japan, Mexi... and more
Vera Therapeutics, Inc.

Recruiting

Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)

IgA Nephropathy | Berger Disease

United States
Novartis Pharmaceuticals

Recruiting

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis (SIRIUS-LN)

Lupus Nephritis

China, United States, Spain, Germany, Korea, Republic of, Italy, Thailand, Hungary, Argentina, Brazil, Singapore, Taiwan, France, Vietnam, Malaysia, Lithuania, Canada, India, Colombia, Romania, United Kingdom, Czechia, Guatemala, Mexico, Eston... and more
Gilead Sciences

Recruiting

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy (ARTISTRY-2)

HIV-1-infection

United States, Puerto Rico
ObsEva SA

Completed

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PRIMROSE 2)

Uterine Fibroids | Heavy Menstrual Bleeding

United States, Bulgaria, Czechia, Hungary, Latvia, Lithuania, Poland, Romania, Ukraine
Gilead Sciences

Completed

Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection

Hepatitis C

Spain, Netherlands, Austria, France, United Kingdom, Italy, Estonia, Germany, Poland, Sweden
Gilead Sciences
Galapagos NV

Completed

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (FINCH 1)

Rheumatoid Arthritis

United States, Italy, Poland, Ukraine, Belgium, Hong Kong, Taiwan, Spain, Israel, Bulgaria, India, Serbia, South Africa, Korea, Republic of, Japan, Russian Federation, Argentina, Germany, New Zealand, Thailand, Hungary, Netherlands, Slovaki... and more
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy (UnchAIN)

Tendinopathy

Germany
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis

Ankylosing Spondyloarthritis

United Kingdom, Korea, Republic of, China, Czechia
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis (FUTURE 2)

Psoriatic Arthritis

Germany, United Kingdom, Belgium, United States, Australia, Thailand, Russian Federation, Czechia, Canada, Poland, Puerto Rico
Novartis Pharmaceuticals

Completed

Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis

Chronic Plaque Psoriasis
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site (ACHILLES)

Psoriatic Arthritis | Enthesitis | Axial Spondyloarthritis

Germany, Spain, United Kingdom, Greece, Bulgaria, Italy, Czechia, Slovakia
Sanofi

Active, not recruiting

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

Secondary Progressive Multiple Sclerosis

United States, Argentina, Belgium, Canada, Czechia, France, Germany, Greece, India, Israel, Netherlands, Norway, Portugal, Turkey, United Kingdom, Japan, Austria, Bulgaria, China, Denmark, Finland, Italy, Lithuania, Poland, Romania, Russian... and more
Gilead Sciences

Completed

Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

Canada, United States, Hong Kong, United Kingdom, Switzerland, New Zealand
Gilead Sciences

Completed

Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon (POSITRON)

Chronic Hepatitis C

United States, Canada, New Zealand, Puerto Rico, Australia
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis

Non-radiographic Axial Spondyloarthritis

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

Myelofibrosis

China
Gilead Sciences

Terminated

Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (STELLAR-4)

Nonalcoholic Steatohepatitis

United States, Spain, Hong Kong, Canada, Belgium, Australia, Taiwan, India, Japan, Korea, Republic of, Singapore, United Kingdom, Israel, Puerto Rico, France, New Zealand, Germany, Austria, Italy, Mexico, Poland, Switzerland
Protalix

Recruiting

A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels

Gout

New Zealand
Gilead Sciences

Terminated

Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis (STELLAR-3)

Nonalcoholic Steatohepatitis

Hong Kong, United States, Spain, United Kingdom, Australia, Taiwan, Belgium, Canada, India, Japan, Korea, Republic of, Singapore, Puerto Rico, France, Israel, Austria, Germany, Italy, Malaysia, New Zealand, Mexico, Poland, Switzerland, Netherlan... and more
Novartis Pharmaceuticals

Completed

Extension in AS: Sustainability of Benefits, Safety and Tolerability (MEASURE 1 ext)

Spondylitis, Ankylosing

Belgium, Germany, Netherlands, France, United States, Bulgaria, Italy, Mexico, Russian Federation, Peru, United Kingdom, Turkey, Canada, Taiwan
Gilead Sciences

Completed

Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

Long QT Syndrome

United States
Gilead Sciences
Galapagos NV

Withdrawn

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy (SEALION1-IR)

Ankylosing Spondylitis
Medicines for Malaria Venture
University of Cape Town

Completed

Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers

Malaria

South Africa
Gilead Sciences

Withdrawn

Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment

Rheumatoid Arthritis
GlaxoSmithKline

Completed

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza (ZORO)

Influenza, Human

Australia, Taiwan, Korea, Republic of, United States, Belgium, Canada, Germany, South Africa, Spain, United Kingdom, New Zealand, Thailand, India, China, Brazil, Hong Kong, Slovakia, Russian Federation, Denmark, Mexico, Czechia, H... and more
Novartis Pharmaceuticals

Completed

24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

Psoriatic Arthritis

United Kingdom, Germany, Italy, Spain, United States, Australia, Bulgaria, Russian Federation, Czechia, Canada, Netherlands, Switzerland, Puerto Rico
Novartis Pharmaceuticals

Completed

Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

Psoriasis, Plaque-type Psoriasis

United States
AstraZeneca

Completed

The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers

Healthy | Memory Impairment

United States
Gilead Sciences
Galapagos NV

Withdrawn

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy (SEALION2-NAÏVE)

Ankylosing Spondylitis
Novartis Pharmaceuticals

Withdrawn

An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound (INTERCEPT)

Psoriasis
Pharmacyclics LLC.
Janssen Research & Development, LLC

Active, not recruiting

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)

Mantle-Cell Lymphoma

France, Canada, Spain, United States, Hungary, Korea, Republic of, Greece, Australia, Netherlands, Belgium, United Kingdom, Czechia, Germany, Poland, Italy, Turkey, Ukraine
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection

HCV Infection

France

Search clinical trials for: Placebo to match Secukinumab, s.c.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations